First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives
Trial Focused On Hispanic, Black And Native Americans
Executive Summary
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
You may also be interested in...
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Synairgen Aims To Disprove Doubts About Interferon Therapy In COVID-19
The UK company surged on early results in the summer – but must prove its therapy’s impact in a Phase III study
'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains
The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports